|
|
||||||||
From UCLA-Geffen School of Medicine (Drs. DeGiorgio and Soss, S. Bunch), Los Angeles; USC-Keck School of Medicine (Dr. Heck), Los Angeles, CA; Mayo Clinic Rochester (Dr. Britton), MN; Borgess Medical Center Research Group (Dr. Green), Kalamazoo, MI; Northeast Regional Epilepsy Group (Dr. Lancman), White Plains, NY; Childrens Mercy Hospital (Dr. Murphy), Kansas City, MO; LSU HSC Epilepsy Center of Excellence (Dr. Olejniczak), New Orleans, LA; University of New Mexico School of Medicine (Dr. Shih), Albuquerque; and SYNERGOS Biomedical Consulting (Dr. Arrambide), The Woodlands, TX.
Address correspondence and reprint requests to Dr. Christopher M. DeGiorgio, Reed Neurological Research Center, 710 Westwood Plaza, C-139 AMDG, Los Angeles, CA 90095; e-mail: cmd{at}mednet.ucla.edu
Vagus nerve stimulation (VNS) is an effective adjunctive treatment for intractable epilepsy. However, the optimal range of device duty-cycles [on/(on + off times)] is poorly understood. The authors performed a multicenter, randomized trial of three unique modes of VNS, which varied primarily by duty-cycle. The results indicate that the three duty-cycles were equally effective. The data support the use of standard duty-cycles as initial therapy.
Supported by a grant from Cyberonics, Inc.
Drs. DeGiorgio, Heck, Britton, Green, Lancman, Murphy, Olejniczak, and Shih have received grant support and honoraria from Cyberonics, Inc. Dr. Arrambide has received consulting fees from Cyberonics, Inc. for statistical consultation. Dr. Soss and S. Bunch have nothing to disclose.
Received October 21, 2004. Accepted in final form April 11, 2005.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |